Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEONNASDAQ:ATNXNYSE:CPHINASDAQ:CTXR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.82+11.7%$0.49$0.38▼$269.28$9.21M0.571.01 million shs643,959 shsATNXAthenex$0.95$0.20▼$23.80$1.76M1.36194,316 shs1.88 million shsCPHIChina Pharma$1.61+6.1%$5.11$1.20▼$3.35$5.26M0.7764,953 shs78,172 shsCTXRCitius Pharmaceuticals$0.85-0.6%$0.85$0.65▼$26.25$8.36M0.9190,438 shs96,211 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma+11.67%+41.49%+69.83%+23.47%-99.27%ATNXAthenex0.00%0.00%0.00%0.00%0.00%CPHIChina Pharma+6.12%+0.81%-13.97%-92.98%-94.26%CTXRCitius Pharmaceuticals-0.56%+23.08%+23.33%-52.46%-94.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEONAEON Biopharma3.2931 of 5 stars3.55.00.00.00.61.71.9ATNXAthenex0.1326 of 5 stars0.00.00.04.10.00.00.0CPHIChina PharmaN/AN/AN/AN/AN/AN/AN/AN/ACTXRCitius Pharmaceuticals2.3607 of 5 stars3.44.00.00.00.60.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEONAEON Biopharma 3.00Buy$360.0044,071.78% UpsideATNXAthenex 0.00N/AN/AN/ACPHIChina Pharma 0.00N/AN/AN/ACTXRCitius Pharmaceuticals 2.80Moderate Buy$54.506,304.23% UpsideCurrent Analyst Ratings BreakdownLatest ATNX, CTXR, CPHI, and AEON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025CTXRCitius PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/23/2025CTXRCitius PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/15/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/AATNXAthenex$102.82M0.00N/AN/A($3.07) per share0.00CPHIChina Pharma$4.30M1.22N/AN/A$0.70 per share2.30CTXRCitius PharmaceuticalsN/AN/AN/AN/A$8.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEONAEON Biopharma-$36.63M$298.124.53N/AN/AN/AN/A-994.63%8/11/2025 (Estimated)ATNXAthenex-$103.43M-$15.88N/AN/AN/A-86.31%-727.79%-44.44%N/ACPHIChina Pharma-$3.08MN/A0.00∞N/A-85.56%-63.93%-31.42%N/ACTXRCitius Pharmaceuticals-$39.14MN/A0.000.68N/AN/A-51.69%-37.60%8/11/2025 (Estimated)Latest ATNX, CTXR, CPHI, and AEON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q2 2025CTXRCitius Pharmaceuticals-$1.08-$1.27-$0.19-$1.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEONAEON BiopharmaN/AN/AN/AN/AN/AATNXAthenexN/AN/AN/AN/AN/ACPHIChina PharmaN/AN/AN/AN/AN/ACTXRCitius PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEONAEON BiopharmaN/A0.220.22ATNXAthenex3.081.090.72CPHIChina Pharma0.220.790.26CTXRCitius PharmaceuticalsN/A0.410.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEONAEON Biopharma22.78%ATNXAthenex30.48%CPHIChina PharmaN/ACTXRCitius Pharmaceuticals16.88%Insider OwnershipCompanyInsider OwnershipAEONAEON Biopharma0.86%ATNXAthenex9.20%CPHIChina Pharma17.32%CTXRCitius Pharmaceuticals12.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEONAEON Biopharma511.31 million74.37 millionNot OptionableATNXAthenex6528.66 million7.87 millionOptionableCPHIChina Pharma2503.26 million15.92 millionNot OptionableCTXRCitius Pharmaceuticals209.83 million7.55 millionOptionableATNX, CTXR, CPHI, and AEON HeadlinesRecent News About These CompaniesCitius Pharmaceuticals, Inc. (NASDAQ:CTXR) Receives $54.50 Average PT from BrokeragesMay 31, 2025 | americanbankingnews.comMaxim Group Downgrades Citius Pharmaceuticals (CTXR)May 24, 2025 | msn.comCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | prnewswire.comCitius Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceMay 5, 2025 | prnewswire.comCitius Pharmaceuticals target adjusted to $4 for split at H.C. WainwrightApril 12, 2025 | markets.businessinsider.comCitius Pharmaceuticals announces $2M registered direct offering of common stockApril 2, 2025 | markets.businessinsider.comCitius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common StockApril 1, 2025 | prnewswire.comCitius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business UpdateFebruary 14, 2025 | prnewswire.comCitius Pharmaceuticals and Citius Oncology announce J-Code issued for LymphirFebruary 6, 2025 | markets.businessinsider.comCitius Pharma's LYMPHIR gains permanent J-code for billingFebruary 6, 2025 | msn.comCitius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid ServicesFebruary 6, 2025 | prnewswire.comCitius Pharmaceuticals announces $3M registered direct offering priced ATMJanuary 8, 2025 | markets.businessinsider.comCitius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesJanuary 8, 2025 | prnewswire.comCitius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025January 7, 2025 | prnewswire.comCitius Oncology weighs strategic options on road to launching newly-approved lymphoma medJanuary 6, 2025 | fiercepharma.comCitius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic AlternativesJanuary 6, 2025 | prnewswire.comD. Boral Capital Upgrades Citius Pharmaceuticals (CTXR)December 30, 2024 | msn.comCitius Pharmaceuticals upgraded to Buy from Hold at D. Boral CapitalDecember 30, 2024 | markets.businessinsider.comCitius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides ...December 28, 2024 | gurufocus.comCitius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business UpdateDecember 27, 2024 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATNX, CTXR, CPHI, and AEON Company DescriptionsAEON Biopharma NASDAQ:AEON$0.82 +0.09 (+11.67%) Closing price 06/6/2025 03:58 PM EasternExtended Trading$0.80 -0.02 (-2.45%) As of 06/6/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Athenex NASDAQ:ATNXAthenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.China Pharma NYSE:CPHI$1.61 +0.09 (+6.12%) Closing price 06/6/2025 03:59 PM EasternExtended Trading$1.62 +0.01 (+0.43%) As of 06/6/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.Citius Pharmaceuticals NASDAQ:CTXR$0.85 0.00 (-0.56%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$0.86 +0.01 (+1.18%) As of 06/6/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
